Abcam, ab280101, Human PARK2 (Parkin) knockout SH-SY5Y cell lysate

Size: 1Kit
PRKN KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 77 bp Deletion in Exon 5.
Key facts
Cell type:SH-SY5Y,
Species or organism:Human,
Tissue:Bone marrow,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 77 bp Deletion in Exon 5,
Disease:Neuroblastoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PRKN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Parkin protein also known as PRK8 or Park2 is an E3 ubiquitin ligase with a molecular weight of approximately 52 kDa. This protein plays a critical role in tagging damaged proteins for degradation maintaining cellular health. Parkin is expressed in various tissues with significant levels in dopaminergic neurons in the brain. It is encoded by the PARK2 gene and has been linked to the regulation of mitochondrial quality and autophagy processes contributing to cellular homeostasis.
Biological function summary
Parkin is essential for the regulation of mitochondria through its involvement in the mitochondrial quality control system. It functions as part of a complex with other proteins that respond to mitochondrial damage by tagging them with ubiquitin molecules. This mechanism allows for the removal of defective mitochondria via mitophagy critical for preventing the accumulation of damaged cellular components.
Pathways
Parkin interacts with pathways involved in the cellular stress response particularly the PINK1 (PTEN Induced Kinase
pathway. PINK1 phosphorylates Parkin activating it to label damaged mitochondria. Another critical pathway involves proteasomal degradation where Parkin collaborates with Ubiquitin to manage protein turnover. These pathways highlight its relationships with other cellular stress-regulating proteins enhancing our understanding of its roles in maintaining cellular integrity.
Mutations in the gene coding for Parkin are linked to Parkinson's disease (PD) and some forms of juvenile autosomal recessive parkinsonism. The Parkin protein's dysfunctional activity leads to impaired mitochondrial management and protein aggregation in neurons contributing significantly to neurodegenerative disease. In conditions such as PD Parkin interacts with other proteins such as PINK1 reinforcing its role in mitochondrial protection and indicating the protein's importance in disease progression and potential therapeutic targeting.